News | March 17, 2024
Sumitomo Pharma announces availability of ORGOVYX in Canada
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
Sharma joined the Morepen Lab in 2004
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
Subscribe To Our Newsletter & Stay Updated
